by Commetric | May 13, 2022
As pharma experiences continued momentum for immuno-oncology treatments, with the current drug development pipeline consisting of thousands of potential therapies and therapy combinations, the media conversation around immuno-oncology is becoming livelier and...
by Commetric | Feb 4, 2022
During the pandemic, global health diseases have been discussed in two main ways: as being put on the sidelines because of the immediate threat of Covid, or as being finally treatable thanks to the advances in vaccine science turbocharged by the crisis. Our media...
by Commetric | Jan 11, 2022
As COVID-19 has unequally affected many racial and ethnic minority groups, the crisis served as a call to action within the public health community, spurring pharma to pursue actionable efforts toward reversing health inequity. Our media analysis found that the top...
by Commetric | Jan 4, 2022
While the presidential election, the pandemic and racial reckoning were stories that drove intense interest and engagement to news outlets in 2020, some metrics suggest that 2021 represented the inevitable hangover: engagement with news content plummeted...
by Commetric | Feb 18, 2021
Our recent pharma analysis concluded that journalists have started to report more favourably of pharma’s work and that companies are experiencing a reputational boost as the pandemic highlights their role in developing medications and vaccines. This comes at a time...
